[go: up one dir, main page]

AR109253A1 - COMPOSITION OF TENELIGLIPTINE AND METFORMIN AND PROCESS TO PREPARE IT - Google Patents

COMPOSITION OF TENELIGLIPTINE AND METFORMIN AND PROCESS TO PREPARE IT

Info

Publication number
AR109253A1
AR109253A1 ARP170101849A ARP170101849A AR109253A1 AR 109253 A1 AR109253 A1 AR 109253A1 AR P170101849 A ARP170101849 A AR P170101849A AR P170101849 A ARP170101849 A AR P170101849A AR 109253 A1 AR109253 A1 AR 109253A1
Authority
AR
Argentina
Prior art keywords
metformin
pharmaceutically acceptable
pharmaceutical composition
teneligliptine
prepare
Prior art date
Application number
ARP170101849A
Other languages
Spanish (es)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61196457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR109253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of AR109253A1 publication Critical patent/AR109253A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica en la forma de comprimido oral recubierto, con Teneligliptina o sus sales farmacéuticamente aceptables y Metformina o sus sales farmacéuticamente aceptables para el tratamiento de diabetes mellitus tipo 2. Dicha composición farmacéutica es obtenida por granulación húmeda, utilizando Metformina molida a polvo fino y baja carga de excipientes, consistentes en un aglutinante, en este caso Povidona y Estearato de Magnesio como lubricante durante la compresión.Pharmaceutical composition in the form of a coated oral tablet, with Teneligliptin or its pharmaceutically acceptable salts and Metformin or its pharmaceutically acceptable salts for the treatment of type 2 diabetes mellitus. Said pharmaceutical composition is obtained by wet granulation, using fine and low ground powder Metformin loading of excipients, consisting of a binder, in this case Povidone and Magnesium Stearate as a lubricant during compression.

ARP170101849A 2016-08-17 2017-07-04 COMPOSITION OF TENELIGLIPTINE AND METFORMIN AND PROCESS TO PREPARE IT AR109253A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016010682A MX384961B (en) 2016-08-17 2016-08-17 IMPROVED COMPOSITION OF TENELIGLIPTIN AND METFORMIN AND PROCESS FOR PREPARING SAME.

Publications (1)

Publication Number Publication Date
AR109253A1 true AR109253A1 (en) 2018-11-14

Family

ID=61196457

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101849A AR109253A1 (en) 2016-08-17 2017-07-04 COMPOSITION OF TENELIGLIPTINE AND METFORMIN AND PROCESS TO PREPARE IT

Country Status (8)

Country Link
AR (1) AR109253A1 (en)
CL (1) CL2019000273A1 (en)
CO (1) CO2019001110A2 (en)
DO (1) DOP2019000035A (en)
EC (2) ECSP19010066A (en)
MX (1) MX384961B (en)
PE (1) PE20190402A1 (en)
WO (1) WO2018033808A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
WO2015132679A1 (en) * 2014-03-05 2015-09-11 Glenmark Pharmaceuticals Ltd Teneligliptin compositions

Also Published As

Publication number Publication date
CO2019001110A2 (en) 2019-04-12
DOP2019000035A (en) 2019-06-30
BR112019002909A2 (en) 2019-05-21
MX2016010682A (en) 2018-02-16
WO2018033808A1 (en) 2018-02-22
CL2019000273A1 (en) 2019-06-28
MX384961B (en) 2025-03-14
ECSP19044926A (en) 2019-07-31
ECSP19010066A (en) 2019-11-30
PE20190402A1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
JP2017509667A5 (en)
MX372673B (en) A BTK INHIBITOR FOR USE IN THE TREATMENT OF PEMPHIGUUS AND SALTS AND SOLID FORMS THEREOF.
MX383499B (en) THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES
CL2016000117A1 (en) Autotaxin inhibitors comprise a heteroaromatic ring-benzylamine basic cycle
MX2017008386A (en) Site specific dosing of a btk inhibitor.
SV2018005682A (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
BR112016015838A8 (en) heterocyclic aromatic compounds, pharmaceutical composition comprising said compounds and combination product
JP2016518337A5 (en)
MX2016011810A (en) Pharmaceutical compositions of therapeutically active compounds.
CO2017005834A2 (en) Modified-release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
NZ733670A (en) Insulin glargine/lixisenatide fixed ratio formulation
MX2016011105A (en) Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders.
AR094707A1 (en) COMPOUND OF QUINAZOLIN-4-AMINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE TREATMENT OF A DISEASE MEDIATED BY THE RIP2 KINASE
AR104755A1 (en) METHOD FOR THE TREATMENT OF NEUROLOGICAL DISEASE
JP2017061576A5 (en)
MX2019002369A (en) COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH A MITOCHONDRIAL DYSFUNCTION.
CR20150646A (en) 4- (5- (4-CHLOROPHENYL) -2- (2-CYCLOPROPYLACETIL) -1,4-DIMETHYL-1H-PIRROL-3-IL) BENCENOSULPHONAMIDE AS A NACHR ALFA MODULATOR
AR109253A1 (en) COMPOSITION OF TENELIGLIPTINE AND METFORMIN AND PROCESS TO PREPARE IT
DOP2016000325A (en) COMPOUNDS, PHARMACEUTICAL COMPOSITION AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
MX384394B (en) COMPOUND FOR USE IN THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES.
ECSP20003493A (en) PHARMACEUTICAL COMPOSITIONS
ES2537905B2 (en) Use of 12-deoxiforboles to promote the proliferation of neural stem cells
JP2017516883A5 (en)
ES2548927B1 (en) Purine derivatives as Dapk-1 inhibitors

Legal Events

Date Code Title Description
FC Refusal